Cargando…
Allogeneic CAR-T Cells: More than Ease of Access?
Patient derived anti-CD19 chimeric antigen receptor-T (CAR-T) cells are a powerful tool in achieving a complete remission in a range of B-cell malignancies, most notably B-acute lymphoblastic leukaemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL). However, there are limitations, including inabi...
Autores principales: | Graham, Charlotte, Jozwik, Agnieszka, Pepper, Andrea, Benjamin, Reuben |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6210057/ https://www.ncbi.nlm.nih.gov/pubmed/30275435 http://dx.doi.org/10.3390/cells7100155 |
Ejemplares similares
-
Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors
por: Metelo, Ana M., et al.
Publicado: (2022) -
Allogeneic CAR Cell Therapy—More Than a Pipe Dream
por: Caldwell, Kenneth J., et al.
Publicado: (2021) -
Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia
por: Dupouy, Sandra, et al.
Publicado: (2022) -
Gene-edited healthy donor CAR T cells show superior anti-tumour activity compared to CAR T cells derived from patients with lymphoma in an in vivo model of high-grade lymphoma
por: Graham, Charlotte Elizabeth, et al.
Publicado: (2021) -
Recent Advances in Allogeneic CAR-T Cells
por: Kim, Dong Wook, et al.
Publicado: (2020)